Related Experiment Videos
Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis
T Kanesaka1, M Mori, T Hattori
1Department of Neurology, Chiba University School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670 Japan. kane2000@f7.dion.ne.jp
Background:
Adhesion molecules and matrix metalloproteinases (MMPs) are known to be relevant to the ongoing development and disappearance of areas of demyelination in the white matter of the CNS of multiple sclerosis (MS) patients. This study examined whether serum matrix metalloproteinase-3 (MMP-3) levels correlate with disease activity in MS.
Methods:
Serum MMP-3 levels in 47 consecutive patients with relapsing-remitting MS were measured by immunoassay every 4 weeks over a 15 month period.
Results:
During the study period, 48 clinical relapses occurred. Serum MMP-3 levels within 1 month of relapse were significantly higher than during the remission phase. Sequential analysis showed that serum MMP-3 levels had increased transiently at the time of clinical relapse but returned to the normal range within a month.
Conclusions:
Circulatory MMP-3 levels are correlated with disease activity in relapsing-remitting MS. This may contribute to the breakdown of the blood-brain barrier at the time of relapse.
Insights
Serum matrix metalloproteinase-3 (MMP-3) levels rise during multiple sclerosis (MS) relapses. These elevated MMP-3 levels in MS patients return to normal within a month after relapse, indicating a correlation with disease activity.
Area of Science:
- Neuroimmunology
- Biochemistry
Background:
- Adhesion molecules and matrix metalloproteinases (MMPs) are implicated in demyelination dynamics in multiple sclerosis (MS).
- Understanding the role of specific MMPs, like MMP-3, in MS disease activity is crucial.
Purpose of the Study:
- To investigate the correlation between serum matrix metalloproteinase-3 (MMP-3) levels and disease activity in patients with relapsing-remitting MS.
Main Methods:
- Serum MMP-3 levels were measured using immunoassay in 47 relapsing-remitting MS patients.
- Measurements were taken every 4 weeks over a 15-month period to track changes relative to disease course.
Main Results:
- A total of 48 clinical relapses were observed during the study.
- Serum MMP-3 levels were significantly elevated within one month preceding and during clinical relapses compared to remission phases.
- Transient increases in serum MMP-3 levels at relapse returned to normal within a month.
Conclusions:
- Circulating MMP-3 levels are demonstrably correlated with disease activity in relapsing-remitting MS.
- Elevated MMP-3 during relapse may contribute to blood-brain barrier disruption in MS patients.
